Healio

FDA approves subcutaneous Entyvio as maintenance therapy for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Morningstar

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...
Monthly Prescribing Reference

Entyvio for Subcutanous Administration Approved for Ulcerative Colitis

Credit: Takeda. Entyvio for SC use is expected to be available by the end of October 2023. The Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of Entyvio ® ...
Becker's ASC

Entyvio improves moderate-to-severe ulcerative colitis, Crohn’s

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
Business Insider

New Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative Colitis and Crohn's Disease

Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company ...
Nasdaq

Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced interim results from the VISIBLE open-label extension (OLE) study on the long-term ...
Medscape

FDA OKs Subcutaneous Vedolizumab (Entyvio) for UC Maintenance Therapy

The US Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of vedolizumab (Entyvio SC, Takeda) for maintenance therapy in adults with moderately to severely active ...
The Reporter

Use of Takeda’s Entyvio SC in Inflammatory Bowel Disease Has Slowed Considerably in the EU5 as Gastroenterologists Eye Potential New Launches Later This Year

EXTON, Pa., June 8, 2021 /PRNewswire/ — A few months after the European Medicines Agency (EMA) approved Takeda’s subcutaneous formulation of Entyvio, known as Entyvio SC, Spherix captured the initial ...
Nasdaq

Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License ...
Business Insider

New Real-World Data Analyses Support the Long-Term Use of Entyvio® (vedolizumab) in Bio-Naïve Patients for the Treatment of Moderate to Severe Ulcerative Colitis or Crohn's ...

DEERFIELD, Ill., Oct. 8, 2018 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., ("Takeda") today announced the presentation of new long-term efficacy real-world data analyses for Entyvio ® ...